I'd like to tell you about a patient named Donna. In this photograph, Donna was in her mid-70s, a vigorous, healthy woman, the matriarch of a large clan. She had a family history of heart disease, however, and one day, she had the sudden onset of crushing chest pain. Now unfortunately, rather than seeking medical attention, Donna took to her bed for about 12 hours until the pain passed. The next time she went to see her physician, he performed an electrocardiogram, and this showed that she'd had a large heart attack, or a "myocardial infarction" in medical parlance.
After this heart attack, Donna was never quite the same. Her energy levels progressively waned, she couldn't do a lot of the physical activities she'd previously enjoyed. It got to the point where she couldn't keep up with her grandkids, and it was even too much work to go out to the end of the driveway to pick up the mail. One day, her granddaughter came by to walk the dog, and she found her grandmother dead in the chair. Doctors said it was a cardiac arrhythmia that was secondary to heart failure. But the last thing that I should tell you is that Donna was not just an ordinary patient. Donna was my mother.
Stories like ours are, unfortunately, far too common. Heart disease is the number one killer in the entire world. In the United States, it's the most common reason patients are admitted to the hospital, and it's our number one health care expense. We spend over a 100 billion dollars—billion with a "B"—in this country every year on the treatment of heart disease. Just for reference, that's more than twice the annual budget of the state of Washington.
What makes this disease so deadly? Well, it all starts with the fact that the heart is the least regenerative organ in the human body. Now, a heart attack happens when a blood clot forms in a coronary artery that feeds blood to the wall of the heart. This plugs the blood flow, and the heart muscle is very metabolically active, and so it dies very quickly, within just a few hours of having its blood flow interrupted. Since the heart can't grow back new muscle, it heals by scar formation. This leaves the patient with a deficit in the amount of heart muscle that they have. And in too many people, their illness progresses to the point where the heart can no longer keep up with the body's demand for blood flow. This imbalance between supply and demand is the crux of heart failure.
So when I talk to people about this problem, I often get a shrug and a statement to the effect of, "Well, you know, Chuck, we've got to die of something."
And yeah, but what this also tells me is that we've resigned ourselves to this as the status quo because we have to. Or do we? I think there's a better way, and this better way involves the use of stem cells as medicines.
So what, exactly, are stem cells? If you look at them under the microscope, there's not much going on. They're just simple little round cells. But that belies two remarkable attributes. The first is they can divide like crazy. So I can take a single cell, and in a month's time, I can grow this up to billions of cells. The second is they can differentiate or become more specialized, so these simple little round cells can turn into skin, can turn into brain, can turn into kidney and so forth. Now, some tissues in our bodies are chock-full of stem cells. Our bone marrow, for example, cranks out billions of blood cells every day. Other tissues like the heart are quite stable, and as far as we can tell, the heart lacks stem cells entirely. So for the heart, we're going to have to bring stem cells in from the outside, and for this, we turn to the most potent stem cell type, the pluripotent stem cell. Pluripotent stem cells are so named because they can turn into any of the 240-some cell types that make up the human body.
So this is my big idea: I want to take human pluripotent stem cells, grow them up in large numbers, differentiate them into cardiac muscle cells and then take them out of the dish and transplant them into the hearts of patients who have had heart attacks. I think this is going to reseed the wall with new muscle tissue, and this will restore contractile function to the heart.
Now, before you applaud too much, this was my idea 20 years ago.
And I was young, I was full of it, and I thought, five years in the lab, and we'll crank this out, and we'll have this into the clinic. Let me tell you what really happened.
We began with the quest to turn these pluripotent stem cells into heart muscle. And our first experiments worked, sort of. We got these little clumps of beating human heart muscle in the dish, and that was cool, because it said, in principle, this should be able to be done. But when we got around to doing the cell counts, we found that only one out of 1,000 of our stem cells were actually turning into heart muscle. The rest was just a gemisch of brain and skin and cartilage and intestine. So how do you coax a cell that can become anything into becoming just a heart muscle cell?
Well, for this we turned to the world of embryology. For over a century, the embryologists had been pondering the mysteries of heart development. And they had given us what was essentially a Google Map for how to go from a single fertilized egg all the way over to a human cardiovascular system. So we shamelessly absconded all of this information and tried to make human cardiovascular development happen in a dish. It took us about five years, but nowadays, we can get 90 percent of our stem cells to turn into cardiac muscle—a 900-fold improvement. So this was quite exciting.
This slide shows you our current cellular product. We grow our heart muscle cells in little three-dimensional clumps called cardiac organoids. Each of them has 500 to 1,000 heart muscle cells in it. If you look closely, you can see these little organoids are actually twitching; each one is beating independently. But they've got another trick up their sleeve. We took a gene from jellyfish that live in the Pacific Northwest, and we used a technique called genome editing to splice this gene into the stem cells. And this makes our heart muscle cells flash green every time they beat.
OK, so now we were finally ready to begin animal experiments. We took our cardiac muscle cells and we transplanted them into the hearts of rats that had been given experimental heart attacks. A month later, I peered anxiously down through my microscope to see what we had grown, and I saw...nothing. Everything had died. But we persevered on this, and we came up with a biochemical cocktail that we called our "pro-survival cocktail," and this was enough to allow our cells to survive through the stressful process of transplantation. And now when I looked through the microscope, I could see this fresh, young, human heart muscle growing back in the injured wall of this rat's heart. So this was getting quite exciting.
The next question was: Will this new muscle beat in synchrony with the rest of the heart? So to answer that, we returned to the cells that had that jellyfish gene in them. We used these cells essentially like a space probe that we could launch into a foreign environment and then have that flashing report back to us about their biological activity. What you're seeing here is a zoomed-in view, a black-and-white image of a guinea pig's heart that was injured and then received three grafts of our human cardiac muscle. So you see those sort of diagonally running white lines. Each of those is a needle track that contains a couple of million human cardiac muscle cells in it. And when I start the video, you can see what we saw when we looked through the microscope. Our cells are flashing, and they're flashing in synchrony, back through the walls of the injured heart.
What does this mean? It means the cells are alive, they're well, they're beating, and they've managed to connect with one another so that they're beating in synchrony. But it gets even more interesting than this. If you look at that tracing that's along the bottom, that's the electrocardiogram from the guinea pig's own heart. And if you line up the flashing with the heartbeat that's shown on the bottom, what you can see is there's a perfect one-to-one correspondence. In other words, the guinea pig's natural pacemaker is calling the shots, and the human heart muscle cells are following in lockstep like good soldiers.
Our current studies have moved into what I think is going to be the best possible predictor of a human patient, and that's into macaque monkeys. This next slide shows you a microscopic image from the heart of a macaque that was given an experimental heart attack and then treated with a saline injection. This is essentially like a placebo treatment to show the natural history of the disease. The macaque heart muscle is shown in red, and in blue, you see the scar tissue that results from the heart attack. So as you look as this, you can see how there's a big deficiency in the muscle in part of the wall of the heart. And it's not hard to imagine how this heart would have a tough time generating much force.
Now in contrast, this is one of the stem-cell-treated hearts. Again, you can see the monkey's heart muscle in red, but it's very hard to even see the blue scar tissue, and that's because we've been able to repopulate it with the human heart muscle, and so we've got this nice, plump wall.
OK, let's just take a second and recap. I've showed you that we can take our stem cells and differentiate them into cardiac muscle. We've learned how to keep them alive after transplantation, we've showed that they beat in synchrony with the rest of the heart, and we've shown that we can scale them up into an animal that is the best possible predictor of a human's response. You'd think that we hit all the roadblocks that lay in our path, right? Turns out, not.
These macaque studies also taught us that our human heart muscle cells created a period of electrical instability. They caused ventricular arrhythmias, or irregular heartbeats, for several weeks after we transplanted them. This was quite unexpected, because we hadn't seen this in smaller animals. We've studied it extensively, and it turns out that it results from the fact that our cellular graphs are quite immature, and immature heart muscle cells all act like pacemakers. So what happens is, we put them into the heart, and there starts to be a competition with the heart's natural pacemaker over who gets to call the shots. It would be sort of like if you brought a whole gaggle of teenagers into your orderly household all at once, and they don't want to follow the rules and the rhythms of the way you run things, and it takes a while to rein everybody in and get people working in a coordinated fashion. So our plans at the moment are to make the cells go through this troubled adolescence period while they're still in the dish, and then we'll transplant them in in the post-adolescent phase, where they should be much more orderly and be ready to listen to their marching orders. In the meantime, it turns out we can actually do quite well by treating with anti-arrhythmia drugs as well.
So one big question still remains, and that is, of course, the whole purpose that we set out to do this: Can we actually restore function to the injured heart? To answer this question, we went to something that's called "left ventricular ejection fraction." Ejection fraction is simply the amount of blood that is squeezed out of the chamber of the heart with each beat. Now, in healthy macaques, like in healthy people, ejection fractions are about 65 percent. After a heart attack, ejection fraction drops down to about 40 percent, so these animals are well on their way to heart failure. In the animals that receive a placebo injection, when we scan them a month later, we see that ejection fraction is unchanged, because the heart, of course, doesn't spontaneously recover. But in every one of the animals that received a graft of human cardiac muscle cells, we see a substantial improvement in cardiac function. This averaged eight points, so from 40 to 48 percent. What I can tell you is that eight points is better than anything that's on the market right now for treating patients with heart attacks. It's better than everything we have put together. So if we could do eight points in the clinic, I think this would be a big deal that would make a large impact on human health.
But it gets more exciting. That was just four weeks after transplantation. If we extend these studies out to three months, we get a full 22-point gain in ejection fraction.
Function in these treated hearts is so good that if we didn't know up front that these animals had had a heart attack, we would never be able to tell from their functional studies.
Going forward, our plan is to start phase one, first in human trials here at the University of Washington in 2020—two short years from now. Presuming these studies are safe and effective, which I think they're going to be, our plan is to scale this up and ship these cells all around the world for the treatment of patients with heart disease. Given the global burden of this illness, I could easily imagine this treating a million or more patients a year.
So I envision a time, maybe a decade from now, where a patient like my mother will have actual treatments that can address the root cause and not just manage her symptoms. This all comes from the fact that stem cells give us the ability to repair the human body from its component parts.
In the not-too-distant future, repairing humans is going to go from something that is far-fetched science fiction into common medical practice. And when this happens, it's going to have a transformational effect that rivals the development of vaccinations and antibiotics.
Thank you for your attention.
